Format

Send to

Choose Destination
Br J Cancer. 2018 Apr;118(7):936-937. doi: 10.1038/s41416-018-0045-6. Epub 2018 Mar 16.

New opportunities for kinase drug repurposing and target discovery.

Knapp S1,2,3,4.

Author information

1
Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, Frankfurt, D-60438, Germany. knapp@pharmchem.uni-frankfurt.de.
2
Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, Frankfurt, D-60438, Germany. knapp@pharmchem.uni-frankfurt.de.
3
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. knapp@pharmchem.uni-frankfurt.de.
4
German Cancer Network (DKTK), Frankfurt/Mainz site, Frankfurt, D-60438, Germany. knapp@pharmchem.uni-frankfurt.de.

Abstract

Protein kinases are major drug targets for oncology. The large size of the kinome, active site conservation and the influence of activation states on drug binding complicates the analysis of their cellular mode of action. In a recent article in Science, Klaeger et al. analysed cellular targets of 243 drug candidates providing a large repository of data for drug repurposing.

PMID:
29545596
PMCID:
PMC5931101
DOI:
10.1038/s41416-018-0045-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center